Cargando…

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huygens, Sammy, Oude Munnink, Bas, Gharbharan, Arvind, Koopmans, Marion, Rijnders, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384506/ https://www.ncbi.nlm.nih.gov/pubmed/35867699 http://dx.doi.org/10.1093/cid/ciac601

Ejemplares similares

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
por: Huygens, Sammy, et al.
Publicado: (2023)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
por: Huygens, Sammy, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

A64 Viral sequence classification using deep learning algorithms
por: Nieuwenhuijse, David, et al.
Publicado: (2019)

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution
por: Monrad, Ida, et al.
Publicado: (2021)

Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person
por: Munnink, Bas B. Oude, et al.
Publicado: (2022)

Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients
por: Haidar, Ghady, et al.
Publicado: (2023)

viromeBrowser: A Shiny App for Browsing Virome Sequencing Analysis Results
por: Nieuwenhuijse, David F., et al.
Publicado: (2021)

Evidence-based dosing of convalescent plasma for COVID-19 in future trials
por: Rijnders, Bart J.A., et al.
Publicado: (2022)

Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication
por: Gordon, Claire L, et al.
Publicado: (2021)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation
por: Marcacci, Gianpaolo, et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
por: Oude Munnink, Bas B., et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Children and Utility of Rapid Antigen Testing as an Indicator of Culturable Virus
por: Lohse, Zoe M, et al.
Publicado: (2022)

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
por: Gharbharan, Arvind, et al.
Publicado: (2021)

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
por: Mader, Anna-Lena, et al.
Publicado: (2022)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

Novel opportunities for NGS-based one health surveillance of foodborne viruses
por: Desdouits, Marion, et al.
Publicado: (2020)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

(583) Sotrovimab in Heart Transplant Recipients with Covid-19 in the Omicron Era: A National Transplant Center Experience
por: Garcia, C.N. Perez, et al.
Publicado: (2023)

Mutational analysis of severe acute respiratory syndrome coronavirus 2 in immunocompromised patients with persistent viral detection using whole genome sequencing
por: Chang, Euijin, et al.
Publicado: (2023)

Decreased Risk of Coronavirus Disease 2019–Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
por: Ridgway, Jessica P, et al.
Publicado: (2022)

Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
por: Mambelli, Emanuele, et al.
Publicado: (2022)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era
por: Kang, Yu Ri, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c2lodmoeh0sjs6t55vsc33mvl1